INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28801, 28295, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28802, 28296, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28803, 28297, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28804, 28298, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28805, 28329, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28806, 28330, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28807, 28333, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28808, 28334, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28809, 28339, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28810, 30387, 'Topiramate', 'Nephrolithiasis', 'The use of topiramate may infrequently be associated with the development of kidney stones.  The reported incidence was 1.5% (32 of 2,086 patients) during premarketing use, which is about 2 to 4 times that expected in a similar, untreated population.  Topiramate is a weak carbonic anhydrase inhibitor and may promote stone formation by reducing urinary citrate excretion and increasing urinary pH.  Therapy with topiramate should be administered cautiously with adequate hydration in patients with a history of nephrolithiasis.  The concomitant use of topiramate with other carbonic anhydrase inhibitors should be avoided.  Patients who are dehydrated may be at increased risk for the development of nephrolithiasis and should be encouraged to consume additional amounts of liquid during topiramate therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28811, 0, 'Torasemide', 'Anuria', 'The use of loop diuretics is contraindicated in patients with anuria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28812, 0, 'Torasemide', 'Fibrosis', 'Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites.  Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia.  Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis.  Loop diuretics should be withheld in patients with hepatic coma until the condition improves.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28813, 0, 'Torasemide', 'Water-Electrolyte Imbalance', 'The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium.  Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest.  Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening.  Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow.  Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction.  Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status.  Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy.  Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients.  The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic.  Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28814, 0, 'Torasemide', 'Ototoxicity', 'Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics.  Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents.  Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect.  High-dose parenteral therapy should be administered as controlled infusion.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28815, 0, 'Torasemide', 'Kidney Diseases', 'Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction.  These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss).  Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function.  Prolongation of the dosing intervals may be appropriate to prevent drug accumulation.  The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting.  Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow.  If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28816, 0, 'Torasemide', 'Diabetes Mellitus', 'Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests.  Rarely, precipitation of diabetes mellitus has been reported.  Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28817, 0, 'Torasemide', 'Hyperuricemia', 'Loop diuretics may decrease the rate of uric acid excretion.  Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with loop diuretics should be administered cautiously in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28818, 6268, 'Topotecan', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28819, 18133, 'Topotecan', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28820, 20589, 'Topotecan', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28821, 28340, 'Topotecan', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28822, 28341, 'Topotecan', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28823, 6268, 'Topotecan', 'Hemorrhagic Disorders', 'Topotecan induces myelosuppression.  Severe thrombocytopenia (< 25,000/mm3) has been reported during topotecan therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until platelet counts exceed 100,000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28824, 18133, 'Topotecan', 'Hemorrhagic Disorders', 'Topotecan induces myelosuppression.  Severe thrombocytopenia (< 25,000/mm3) has been reported during topotecan therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until platelet counts exceed 100,000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28825, 20589, 'Topotecan', 'Hemorrhagic Disorders', 'Topotecan induces myelosuppression.  Severe thrombocytopenia (< 25,000/mm3) has been reported during topotecan therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until platelet counts exceed 100,000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28826, 28340, 'Topotecan', 'Hemorrhagic Disorders', 'Topotecan induces myelosuppression.  Severe thrombocytopenia (< 25,000/mm3) has been reported during topotecan therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until platelet counts exceed 100,000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28827, 28341, 'Topotecan', 'Hemorrhagic Disorders', 'Topotecan induces myelosuppression.  Severe thrombocytopenia (< 25,000/mm3) has been reported during topotecan therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena.  Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until platelet counts exceed 100,000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28828, 6268, 'Topotecan', 'Bone Marrow Failure Disorders', 'Topotecan induces myelosuppression.  Severe neutropenia (< 500/mm3), severe thrombocytopenia (< 25,000/mm3), and severe anemia (< 8 g/dl) have been reported frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with neutrophil counts < 1500/mm3 and/or platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until neutrophil counts exceed 1000/mm3, platelet counts exceed 100,000/mm3, and/or hemoglobin levels are at least 9 g/dl.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28829, 18133, 'Topotecan', 'Bone Marrow Failure Disorders', 'Topotecan induces myelosuppression.  Severe neutropenia (< 500/mm3), severe thrombocytopenia (< 25,000/mm3), and severe anemia (< 8 g/dl) have been reported frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with neutrophil counts < 1500/mm3 and/or platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until neutrophil counts exceed 1000/mm3, platelet counts exceed 100,000/mm3, and/or hemoglobin levels are at least 9 g/dl.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28830, 20589, 'Topotecan', 'Bone Marrow Failure Disorders', 'Topotecan induces myelosuppression.  Severe neutropenia (< 500/mm3), severe thrombocytopenia (< 25,000/mm3), and severe anemia (< 8 g/dl) have been reported frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with neutrophil counts < 1500/mm3 and/or platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until neutrophil counts exceed 1000/mm3, platelet counts exceed 100,000/mm3, and/or hemoglobin levels are at least 9 g/dl.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28831, 28340, 'Topotecan', 'Bone Marrow Failure Disorders', 'Topotecan induces myelosuppression.  Severe neutropenia (< 500/mm3), severe thrombocytopenia (< 25,000/mm3), and severe anemia (< 8 g/dl) have been reported frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with neutrophil counts < 1500/mm3 and/or platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until neutrophil counts exceed 1000/mm3, platelet counts exceed 100,000/mm3, and/or hemoglobin levels are at least 9 g/dl.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28832, 28341, 'Topotecan', 'Bone Marrow Failure Disorders', 'Topotecan induces myelosuppression.  Severe neutropenia (< 500/mm3), severe thrombocytopenia (< 25,000/mm3), and severe anemia (< 8 g/dl) have been reported frequently.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.  Therapy with topotecan should not be initiated in patients with neutrophil counts < 1500/mm3 and/or platelet counts < 100,000/mm3.  Subsequent courses of topotecan should be withheld until neutrophil counts exceed 1000/mm3, platelet counts exceed 100,000/mm3, and/or hemoglobin levels are at least 9 g/dl.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28833, 6268, 'Topotecan', 'Kidney Diseases', 'Topotecan is partially eliminated by the kidney.  Approximately 30% of topotecan is excreted in the urine.  Plasma clearance of topotecan was reduced 33% in patients with mild renal impairment (creatinine clearance of 40 to 60 mL/min) and 66% in patients with moderate renal impairment (creatinine clearance of 20 to 40 mL/min).  Therapy with topotecan should be administered cautiously and at a reduced dosage in patients with moderate to severe renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28834, 18133, 'Topotecan', 'Kidney Diseases', 'Topotecan is partially eliminated by the kidney.  Approximately 30% of topotecan is excreted in the urine.  Plasma clearance of topotecan was reduced 33% in patients with mild renal impairment (creatinine clearance of 40 to 60 mL/min) and 66% in patients with moderate renal impairment (creatinine clearance of 20 to 40 mL/min).  Therapy with topotecan should be administered cautiously and at a reduced dosage in patients with moderate to severe renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28835, 20589, 'Topotecan', 'Kidney Diseases', 'Topotecan is partially eliminated by the kidney.  Approximately 30% of topotecan is excreted in the urine.  Plasma clearance of topotecan was reduced 33% in patients with mild renal impairment (creatinine clearance of 40 to 60 mL/min) and 66% in patients with moderate renal impairment (creatinine clearance of 20 to 40 mL/min).  Therapy with topotecan should be administered cautiously and at a reduced dosage in patients with moderate to severe renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28836, 28340, 'Topotecan', 'Kidney Diseases', 'Topotecan is partially eliminated by the kidney.  Approximately 30% of topotecan is excreted in the urine.  Plasma clearance of topotecan was reduced 33% in patients with mild renal impairment (creatinine clearance of 40 to 60 mL/min) and 66% in patients with moderate renal impairment (creatinine clearance of 20 to 40 mL/min).  Therapy with topotecan should be administered cautiously and at a reduced dosage in patients with moderate to severe renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28837, 28341, 'Topotecan', 'Kidney Diseases', 'Topotecan is partially eliminated by the kidney.  Approximately 30% of topotecan is excreted in the urine.  Plasma clearance of topotecan was reduced 33% in patients with mild renal impairment (creatinine clearance of 40 to 60 mL/min) and 66% in patients with moderate renal impairment (creatinine clearance of 20 to 40 mL/min).  Therapy with topotecan should be administered cautiously and at a reduced dosage in patients with moderate to severe renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28838, 6268, 'Topotecan', 'Diarrhea', 'Topotecan capsules can cause severe and life-threatening diarrhea that may require hospitalization.  It is recommended to withhold treatment for severe diarrhea.  Manage diarrhea caused by topotecan aggressively and do no administer topotecan capsules to patients with Grade 3 or 4 diarrhea.  Reduce the dose of therapy after recovery to Grade 1 or less.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28839, 18133, 'Topotecan', 'Diarrhea', 'Topotecan capsules can cause severe and life-threatening diarrhea that may require hospitalization.  It is recommended to withhold treatment for severe diarrhea.  Manage diarrhea caused by topotecan aggressively and do no administer topotecan capsules to patients with Grade 3 or 4 diarrhea.  Reduce the dose of therapy after recovery to Grade 1 or less.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28840, 20589, 'Topotecan', 'Diarrhea', 'Topotecan capsules can cause severe and life-threatening diarrhea that may require hospitalization.  It is recommended to withhold treatment for severe diarrhea.  Manage diarrhea caused by topotecan aggressively and do no administer topotecan capsules to patients with Grade 3 or 4 diarrhea.  Reduce the dose of therapy after recovery to Grade 1 or less.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28841, 28340, 'Topotecan', 'Diarrhea', 'Topotecan capsules can cause severe and life-threatening diarrhea that may require hospitalization.  It is recommended to withhold treatment for severe diarrhea.  Manage diarrhea caused by topotecan aggressively and do no administer topotecan capsules to patients with Grade 3 or 4 diarrhea.  Reduce the dose of therapy after recovery to Grade 1 or less.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28842, 28341, 'Topotecan', 'Diarrhea', 'Topotecan capsules can cause severe and life-threatening diarrhea that may require hospitalization.  It is recommended to withhold treatment for severe diarrhea.  Manage diarrhea caused by topotecan aggressively and do no administer topotecan capsules to patients with Grade 3 or 4 diarrhea.  Reduce the dose of therapy after recovery to Grade 1 or less.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28843, 6268, 'Topotecan', 'Lung Diseases, Interstitial', 'Fatal cases of interstitial lung disease (ILD) have occurred with the use of topotecan.  Risk factors include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD and permanently discontinue treatment for confirmed ILD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28844, 18133, 'Topotecan', 'Lung Diseases, Interstitial', 'Fatal cases of interstitial lung disease (ILD) have occurred with the use of topotecan.  Risk factors include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD and permanently discontinue treatment for confirmed ILD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28845, 20589, 'Topotecan', 'Lung Diseases, Interstitial', 'Fatal cases of interstitial lung disease (ILD) have occurred with the use of topotecan.  Risk factors include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD and permanently discontinue treatment for confirmed ILD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28846, 28340, 'Topotecan', 'Lung Diseases, Interstitial', 'Fatal cases of interstitial lung disease (ILD) have occurred with the use of topotecan.  Risk factors include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD and permanently discontinue treatment for confirmed ILD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28847, 28341, 'Topotecan', 'Lung Diseases, Interstitial', 'Fatal cases of interstitial lung disease (ILD) have occurred with the use of topotecan.  Risk factors include a history of ILD, pulmonary fibrosis, lung cancer, thoracic radiation, and use of pneumotoxic drugs and/or colony stimulating factors.  It is recommended to monitor patients for pulmonary symptoms indicative of ILD and permanently discontinue treatment for confirmed ILD.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28848, 4694, 'Toremifene', 'Long QT Syndrome', 'Toremifene has shown to prolong the QTc interval in a dose and concentration related manner, which can result in Torsade de Pointes (ventricular tachycardia), syncope, seizure, and/or death.  Toremifene should not be prescribed to patients with congenital or acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia.  Caution is advised in patients with congestive heart failure, and patients taking other drugs that can prolong the QT interval.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28849, 4694, 'Toremifene', 'Endometrial Hyperplasia', 'Endometrial cancer, endometrial hyperplasia, hypertrophy, and uterine polyps have been reported in some patients treated with toremifene.  Long-term use of toremifene has not been established in patients with preexisting endometrial hyperplasia.  All patients should have baseline and annual gynecological examinations.  In particular, patients at high risk of endometrial cancer should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28850, 4694, 'Toremifene', 'Liver Diseases', 'Hepatotoxicity, hepatitis, and non-alcoholic fatty liver disease have been reported in clinical trials and postmarketing with toremifene.  Liver function tests should be performed periodically.  Caution is advised in patients with any hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28851, 4694, 'Toremifene', 'Thromboembolism', 'Thromboembolic events such as thrombophlebitis and pulmonary embolism have been noted during toremifene therapy.  Patients with an active or past history of thromboembolic events should generally not be administered toremifene.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28852, 9650, 'Tranylcypromine', 'Cerebrovascular Disorders', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with cerebrovascular or cardiovascular disease, including hypertension and congestive heart failure.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  MAOI antidepressants are also commonly associated with dose-related orthostatic hypotension, which occurs most frequently in patients with preexisting hypertension but may be minimized with slow, gradual titration.  Blood pressure should be monitored closely in all patients who receive MAOI therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28853, 9650, 'Tranylcypromine', 'Malignant Carcinoid Syndrome', 'The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with carcinoid syndrome.  Nonspecific MAOIs inhibit the breakdown of pressor amines, including serotonin, and may exacerbate symptoms of the syndrome.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28854, 9650, 'Tranylcypromine', 'Headache', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with a history of headaches.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  Since headache may often be the first symptom of a hypertensive reaction during MAOI therapy, use of these agents is not recommended in patients who experience frequent or severe headaches.  MAOIs should be withdrawn promptly if headaches develop during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28855, 9650, 'Tranylcypromine', 'Hyperthyroidism', 'Nonspecific monoamine oxidase inhibitors (MAOIs) inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  Therapy with nonspecific MAOIs should be administered cautiously in patients with hyperthyroidism, since these patients have an increased sensitivity to pressor amines.  Blood pressure should be monitored closely during therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28856, 9650, 'Tranylcypromine', 'Liver Diseases', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with abnormal liver function tests or a history of liver disease.  A low incidence of altered liver function or hepatocellular jaundice has been reported in association with the use of MAOI antidepressants.  Periodic monitoring of liver function tests is recommended during prolonged and/or high-dose therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28857, 9650, 'Tranylcypromine', 'Pheochromocytoma', 'The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas, that secrete pressor substances.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28858, 9650, 'Tranylcypromine', 'Kidney Diseases', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with severe renal dysfunction.  These drugs may accumulate in plasma when renal function is impaired.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28859, 9650, 'Tranylcypromine', 'Alcoholism', 'The use of monoamine oxidase inhibitors with alcohol or any other CNS depressants is contraindicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28860, 9650, 'Tranylcypromine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28861, 9650, 'Tranylcypromine', 'Cardiovascular disease', 'The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with diagnosed cardiovascular disease, hypertension, or confirmed or suspected cerebrovascular disorders.  These drugs can cause hypertensive crises, which sometimes can be fatal, and are characterized by occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia.  Intracranial bleeding has been reported in some cases in association with the increase in blood pressure.Normotensive patients receiving therapy with MAOIs need to have monitored their blood pressure frequently to detect any evidence of pressor response and treatment should be discontinued immediately if blood pressure increases or the patient reports symptoms such a headaches or palpitations.  Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger an hypertensive crisis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28862, 9650, 'Tranylcypromine', 'Hypoglycemia', 'There is conflicting evidence regarding whether monoamine oxidase inhibitors (MAOIs) affect glucose metabolism or potentiate oral hypoglycemic agents.  Therapy with MAOIs should be administered cautiously in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28863, 9650, 'Tranylcypromine', 'Parkinsonian Disorders', 'Nonspecific monoamine oxidase inhibitors (MAOIs) may increase the frequency and severity of signs and symptoms associated with parkinsonian syndrome.  Therapy with nonspecific MAOIs should be administered cautiously in patients with this disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28864, 9650, 'Tranylcypromine', 'Mental Disorders', 'Monoamine oxidase inhibitor (MAOI) antidepressants may cause excessive stimulation in hyperactive or schizophrenic patients.  Symptoms of psychosis may be aggravated in schizophrenia, particularly that with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  Therapy with MAOI antidepressants should be administered cautiously in patients with hyperactive or hyperexcitable personalities, schizophrenia or bipolar disorder.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28865, 9650, 'Tranylcypromine', 'Seizures', 'Monoamine oxidase inhibitor (MAOI) antidepressants may have variable effects on seizure threshold.  Decreased seizure frequency as well as increased frequency have been reported.  Therapy with MAOI antidepressants should be administered cautiously in patients with a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28866, 9650, 'Tranylcypromine', 'Angina Pectoris', 'Monoamine oxidase inhibitors may have the capacity to suppress anginal pain that would otherwise serve as a warning of myocardial ischemia.  Caution is advised in patients with a history of angina or risk of myocardial infarction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28867, 9650, 'Tranylcypromine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a monoamine oxidase inhibitor (MAOI).  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that MAOIs antidepressants are not approved for use in treating bipolar depression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28868, 9650, 'Tranylcypromine', 'Diabetes Mellitus', 'Monoamine oxidase inhibitors can increase the sensitivity to insulin, and have contributed to hypoglycemic episodes in patients with diabetes.  Caution should be used when prescribing in diabetic patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28869, 9650, 'Tranylcypromine', 'Hypotension', 'Hypotension has been observed during therapy with monoamine oxidase inhibitors.  These drugs should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28870, 15080, 'Benzocaine (topical)', 'Methemoglobinemia', 'Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28871, 17253, 'Benzocaine (topical)', 'Methemoglobinemia', 'Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28872, 19587, 'Benzocaine (topical)', 'Methemoglobinemia', 'Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28873, 19588, 'Benzocaine (topical)', 'Methemoglobinemia', 'Rarely, benzocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with benzocaine should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition except in G-6-PD-deficient patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28874, 0, 'Trametinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28875, 0, 'Trametinib', 'Cardiomyopathies', 'Cardiomyopathy, including cardiac failure may occur with the use of trametinib.  It is recommended that all patients undergo a cardiovascular evaluation including echocardiogram at baseline to document normal left ventricular ejection fraction (LVEF) and repeat echocardiograms at Week 4, Week 12, and every 12 weeks thereafter as clinically appropriate.  Withhold trametinib for up to 4 weeks if absolute LVEF value decreases by 10% from pretreatment values and is less than the lower limit of normal (LLN).  Permanently discontinue trametinib for symptomatic cardiomyopathy or persistent, asymptomatic LV dysfunction of >20% from baseline that is below LLN and that does not resolve within 4 weeks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28876, 0, 'Trametinib', 'Peptic Ulcer Perforation', 'Colitis and gastrointestinal perforation, sometimes with fatal outcomes can occur with the use of trametinib.  Care and close monitoring is recommended with using this agent in patients with gastrointestinal complications.  Monitor patients closely for colitis and gastrointestinal perforations.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28877, 0, 'Trametinib', 'Hemorrhage', 'The use of trametinib may increase the incidence of hemorrhagic events, including major hemorrhages defined as symptomatic bleeding in a critical area or organ.  It is recommended to discontinue the use of trametinib for all Grade 4 hemorrhagic events and temporarily withhold the use of trametinib for Grade 3 hemorrhagic events, if improved, resume the dose at the next lower dose level.  Close monitoring is recommended.  Care should be taken when using this agent in patients at risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28878, 0, 'Trametinib', 'Hepatic Insufficiency', 'Based on a population pharmacokinetic analysis of trametinib, no dose adjustment is recommended in patients with mild hepatic impairment.  There are no data on the pharmacokinetics of trametinib in patients with moderate or severe hepatic impairment.  Close monitoring is recommended for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28879, 0, 'Trametinib', 'Hyperglycemia', 'The use of trametinib may cause hyperglycemia.  It is recommended to monitor serum glucose levels upon initiation of therapy and as clinically appropriate in patients with preexisting diabetes or hyperglycemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28880, 0, 'Trametinib', 'Toxic Optic Neuropathy', 'Ocular toxicities, including retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED) have been reported with the use of trametinib.  It is recommended to perform ophthalmological evaluation periodically and at any time a patient reports visual disturbances.  Permanently discontinue treatment with trametinib in patients with documented RVO, or RPED.  Withhold therapy with trametinib if RPED is diagnosed.  If resolution of the RPED is documented on repeat ophthalmological evaluation within 3 weeks, resume treatment or reduce the dose or discontinue treatment if no improvement.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28881, 0, 'Trametinib', 'Kidney Diseases', 'Based on a population pharmacokinetic analysis of trametinib, no dose adjustment is recommended in patients with mild or moderate renal impairment.  There are no data on the pharmacokinetics of trametinib in patients with severe renal impairment.  Close monitoring is recommended for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28882, 0, 'Trametinib', 'Venous Thromboembolism', 'Venous thromboembolism can occur with trametinib.  It is recommended to permanently discontinue the use of trametinib for life threatening pulmonary embolism and to withhold therapy for uncomplicated deep venous thrombosis and pulmonary embolism for up to 3 weeks or as clinically appropriate and if improved patients should resume treatment at a lower dose as clinically indicated.  Care should be exercised when using this agent in patients at risk.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28883, 10208, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28884, 15363, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28885, 17001, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28886, 17002, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28887, 20325, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28888, 20326, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28889, 20329, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28890, 20330, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28891, 21251, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28892, 21252, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28893, 26563, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28894, 27923, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28895, 28397, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28896, 28447, 'Tranexamic acid', 'Disseminated Intravascular Coagulation', 'The use of tranexamic acid is contraindicated in patients with active intravascular clotting.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28897, 10208, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28898, 15363, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28899, 17001, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (28900, 17002, 'Tranexamic acid', 'Subarachnoid Hemorrhage', 'The use of tranexamic acid is contraindicated in patients with subarachnoid hemorrhage.  Cerebral edema and infarction can occur in patients with subarachnoid hemorrhage.', '3', '', 'DDInter', 0);
